Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, Kurtulmus A, Tomlinson A, Mitrova Z, Foti F, Del Giovane C, Quested DJ, Cowen PJ, Barbui C, Amato L, Efthimiou O, Cipriani A. De Crescenzo F, et al. Among authors: watanabe n. Lancet. 2022 Jul 16;400(10347):170-184. doi: 10.1016/S0140-6736(22)00878-9. Lancet. 2022. PMID: 35843245 Free article.
Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants : a systematic review and meta-analysis.
Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA; Multiple Meta-Analyses of New-Generation Antidepressants (MANGA) Study Group. Nakagawa A, et al. Among authors: watanabe n. CNS Drugs. 2008;22(7):587-602. doi: 10.2165/00023210-200822070-00004. CNS Drugs. 2008. PMID: 18547127 Review.
Milnacipran versus other antidepressive agents for depression.
Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA. Nakagawa A, et al. Among authors: watanabe n. Cochrane Database Syst Rev. 2009 Jul 8;2009(3):CD006529. doi: 10.1002/14651858.CD006529.pub2. Cochrane Database Syst Rev. 2009. PMID: 19588396 Free PMC article. Review.
Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis.
Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA; MANGA (Meta-Analysis of New Generation Antidepressants) Study Group. Watanabe N, et al. CNS Drugs. 2010 Jan;24(1):35-53. doi: 10.2165/11319480-000000000-00000. CNS Drugs. 2010. PMID: 20030418 Review.
Fluvoxamine versus other anti-depressive agents for depression.
Omori IM, Watanabe N, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA. Omori IM, et al. Among authors: watanabe n. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006114. doi: 10.1002/14651858.CD006114.pub2. Cochrane Database Syst Rev. 2010. PMID: 20238342 Free PMC article. Review.
4,408 results